Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

Li Tong; Siddaraju M. Nanjundaiah; Shivaprasad H. Venkatesha; Brian Astry; Hua Yu; Kamal D. Moudgil

doi:10.1016/j.clim.2014.09.014

Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

Li Tong, Siddaraju M. Nanjundaiah, Shivaprasad H. Venkatesha, Brian Astry, Hua Yu, Kamal D. Moudgil

Dermatology

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting the synovial joints. The currently available drugs for RA are effective only in a proportion of patients and their prolonged use is associated with severe adverse effects. Thus, new anti-arthritic agents are being sought. We tested Pristimerin, a naturally occurring triterpenoid, for its therapeutic activity against rat adjuvant arthritis. Pristimerin effectively inhibited both arthritic inflammation and cartilage and bone damage in the joints. Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-γt), coupled with an increase in the immunomodulatory cytokine IL-10. Also increased was IFN-γ, which can inhibit IL-17 response. In addition, the Th17/Treg ratio was altered in favor of immune suppression and the RANKL/OPG ratio was skewed towards anti-osteoclastogenesis. This is the first report on testing Pristimerin in arthritis. We suggest further evaluation of Pristimerin in RA patients.

Original language	English (US)
Pages (from-to)	220-230
Number of pages	11
Journal	Clinical Immunology
Volume	155
Issue number	2
DOIs	https://doi.org/10.1016/j.clim.2014.09.014
State	Published - Dec 1 2014

Bibliographical note

Funding Information:
This work was supported in part by the National Institutes of Health grant R01AT004321 (to KDM). We thank Joseph P. Stains for advice and help in bone histomorphometry experiments; Stefanie Vogel for providing us with RT-PCR facility; Nicholas Ambulos for help with PCR primers; and Lisa Hester for help with cytokine testing.

Publisher Copyright:
© 2014 Elsevier Inc.

Keywords

Autoimmunity
Experimental arthritis
Mediators of inflammation
Natural products
T cell subsets (Th17/Treg)
Therapy

Access

10.1016/j.clim.2014.09.014

OpenUrl availability

Full text

Cite this

Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. / Tong, Li; Nanjundaiah, Siddaraju M.; Venkatesha, Shivaprasad H. et al.
In: Clinical Immunology, Vol. 155, No. 2, 01.12.2014, p. 220-230.

Research output: Contribution to journal › Article › peer-review

@article{c8c002013c964abe91676004d6493935,

title = "Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage",

abstract = "Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting the synovial joints. The currently available drugs for RA are effective only in a proportion of patients and their prolonged use is associated with severe adverse effects. Thus, new anti-arthritic agents are being sought. We tested Pristimerin, a naturally occurring triterpenoid, for its therapeutic activity against rat adjuvant arthritis. Pristimerin effectively inhibited both arthritic inflammation and cartilage and bone damage in the joints. Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-γt), coupled with an increase in the immunomodulatory cytokine IL-10. Also increased was IFN-γ, which can inhibit IL-17 response. In addition, the Th17/Treg ratio was altered in favor of immune suppression and the RANKL/OPG ratio was skewed towards anti-osteoclastogenesis. This is the first report on testing Pristimerin in arthritis. We suggest further evaluation of Pristimerin in RA patients.",

keywords = "Autoimmunity, Experimental arthritis, Mediators of inflammation, Natural products, T cell subsets (Th17/Treg), Therapy",

author = "Li Tong and Nanjundaiah, {Siddaraju M.} and Venkatesha, {Shivaprasad H.} and Brian Astry and Hua Yu and Moudgil, {Kamal D.}",

note = "Funding Information: This work was supported in part by the National Institutes of Health grant R01AT004321 (to KDM). We thank Joseph P. Stains for advice and help in bone histomorphometry experiments; Stefanie Vogel for providing us with RT-PCR facility; Nicholas Ambulos for help with PCR primers; and Lisa Hester for help with cytokine testing. Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.clim.2014.09.014",

language = "English (US)",

volume = "155",

pages = "220--230",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

AU - Tong, Li

AU - Nanjundaiah, Siddaraju M.

AU - Venkatesha, Shivaprasad H.

AU - Astry, Brian

AU - Yu, Hua

AU - Moudgil, Kamal D.

N1 - Funding Information: This work was supported in part by the National Institutes of Health grant R01AT004321 (to KDM). We thank Joseph P. Stains for advice and help in bone histomorphometry experiments; Stefanie Vogel for providing us with RT-PCR facility; Nicholas Ambulos for help with PCR primers; and Lisa Hester for help with cytokine testing. Publisher Copyright: © 2014 Elsevier Inc.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting the synovial joints. The currently available drugs for RA are effective only in a proportion of patients and their prolonged use is associated with severe adverse effects. Thus, new anti-arthritic agents are being sought. We tested Pristimerin, a naturally occurring triterpenoid, for its therapeutic activity against rat adjuvant arthritis. Pristimerin effectively inhibited both arthritic inflammation and cartilage and bone damage in the joints. Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-γt), coupled with an increase in the immunomodulatory cytokine IL-10. Also increased was IFN-γ, which can inhibit IL-17 response. In addition, the Th17/Treg ratio was altered in favor of immune suppression and the RANKL/OPG ratio was skewed towards anti-osteoclastogenesis. This is the first report on testing Pristimerin in arthritis. We suggest further evaluation of Pristimerin in RA patients.

AB - Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting the synovial joints. The currently available drugs for RA are effective only in a proportion of patients and their prolonged use is associated with severe adverse effects. Thus, new anti-arthritic agents are being sought. We tested Pristimerin, a naturally occurring triterpenoid, for its therapeutic activity against rat adjuvant arthritis. Pristimerin effectively inhibited both arthritic inflammation and cartilage and bone damage in the joints. Pristimerin-treated rats exhibited a reduction in the pro-inflammatory cytokines (IL-6, IL-17, IL-18, and IL-23) and the IL-6/IL-17-associated transcription factors (pSTAT3 and ROR-γt), coupled with an increase in the immunomodulatory cytokine IL-10. Also increased was IFN-γ, which can inhibit IL-17 response. In addition, the Th17/Treg ratio was altered in favor of immune suppression and the RANKL/OPG ratio was skewed towards anti-osteoclastogenesis. This is the first report on testing Pristimerin in arthritis. We suggest further evaluation of Pristimerin in RA patients.

KW - Autoimmunity

KW - Experimental arthritis

KW - Mediators of inflammation

KW - Natural products

KW - T cell subsets (Th17/Treg)

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84910045434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910045434&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2014.09.014

DO - 10.1016/j.clim.2014.09.014

M3 - Article

C2 - 25308129

AN - SCOPUS:84910045434

SN - 1521-6616

VL - 155

SP - 220

EP - 230

JO - Clinical Immunology

JF - Clinical Immunology

IS - 2

ER -

Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this